Aberdeen's Wood Group wins pharmaceutical deal in Germany
Energy services giant Wood Group has secured a major contract which sees it build on its move into the pharmaceutical sector.
The Aberdeen-based firm is to take charge of building a new biotechnology plant for GlaxoSmithKline in Marburg, Germany.
The multi-million pound contract will see a division of Wood Group design and project manage the construction of the new meningitis vaccine factory.
It is due to be completed in July 2019.
The contract builds on a relationship Wood Group began 12 years ago with the vaccines division of GSK.
Wood Group's chief executive Robin Watson said the contract shows GSK's confidence in the company's global capabilities.